450 related articles for article (PubMed ID: 29153068)
1. [Atypical profile problem in serological diagnosis of EBV].
Varıcı Balcı FK; Özbek ÖA; Sayıner AA
Mikrobiyol Bul; 2017 Oct; 51(4):378-386. PubMed ID: 29153068
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of primary versus reactivated Epstein-Barr virus infection in patients with VCA IgG-, VCA IgM- and EBNA-1-antibodies and suspected infectious mononucleosis.
Nystad TW; Myrmel H
J Clin Virol; 2007 Apr; 38(4):292-7. PubMed ID: 17336144
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Abbott Architect, Siemens Immulite, bioMerieux Vidas, and Euroimmune assays for determination of Epstein-Barr virus serological diagnosis.
Appak O; Ozkaratas MH; Sayiner AA
J Med Virol; 2021 Nov; 93(11):6309-6316. PubMed ID: 34375007
[TBL] [Abstract][Full Text] [Related]
4. Evaluation the Architect EBV VCA IgM, VCA IgG, and EBNA-1 IgG chemiluminescent immunoassays to assess EBV serostatus prior transplantation.
Maylin S; Feghoul L; Salmona M; Herda A; Mercier-Delarue S; Simon F; Legoff J
J Med Virol; 2017 Nov; 89(11):2003-2010. PubMed ID: 28661055
[TBL] [Abstract][Full Text] [Related]
5. The impact of serological features in Chinese children with primary or past Epstein-Barr virus infections.
Huang Y; Wei C; Zheng K; Zhao D
Virol J; 2013 Feb; 10():55. PubMed ID: 23406068
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Architect Epstein-Barr Virus (EBV) viral capsid antigen (VCA) IgG, VCA IgM, and EBV nuclear antigen 1 IgG chemiluminescent immunoassays for detection of EBV antibodies and categorization of EBV infection status using immunofluorescence assays as the reference method.
Corrales I; Giménez E; Navarro D
Clin Vaccine Immunol; 2014 May; 21(5):684-8. PubMed ID: 24623623
[TBL] [Abstract][Full Text] [Related]
7. Seroepidemiology of EBV and interpretation of the "isolated VCA IgG" pattern.
De Paschale M; Agrappi C; Manco MT; Mirri P; Viganò EF; Clerici P
J Med Virol; 2009 Feb; 81(2):325-31. PubMed ID: 19107979
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of immunoblot-based assay for detecting Epstein-Barr virus viral capsid antibodies].
Altuğlu I; Aksoy A; Zeytinoğlu A; Orman M
Mikrobiyol Bul; 2010 Apr; 44(2):231-6. PubMed ID: 20549957
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the abbot Architect(™) epstein-barr virus viral capsid antigen IgM, viral capsid antigen IgG and nuclear antigen IgG assays in a pediatric and adult population.
Grandjean Lapierre S; Vallières E; Rabaamad L; Labrecque M; Chartrand C; Renaud C
J Clin Virol; 2016 Aug; 81():1-5. PubMed ID: 27258036
[TBL] [Abstract][Full Text] [Related]
10. Association of clinical and serological parameters of systemic lupus erythematosus patients with Epstein-Barr virus antibody profile.
Chougule D; Nadkar M; Rajadhyaksha A; Pandit-Shende P; Surve P; Dawkar N; Khadilkar P; Patwardhan M; Kaveri S; Ghosh K; Pradhan V
J Med Virol; 2018 Mar; 90(3):559-563. PubMed ID: 28734074
[TBL] [Abstract][Full Text] [Related]
11. Serological diagnosis of Epstein-Barr virus infection by novel ELISAs based on recombinant capsid antigens p23 and p18.
Färber I; Hinderer W; Rothe M; Lang D; Sonneborn HH; Wutzler P
J Med Virol; 2001 Apr; 63(4):271-6. PubMed ID: 11241457
[TBL] [Abstract][Full Text] [Related]
12. Anti-Epstein-Barr virus antibodies in Beijing during 2013-2017: What we have found in the different patients.
Cui J; Yan W; Xu S; Wang Q; Zhang W; Liu W; Ni A
PLoS One; 2018; 13(3):e0193171. PubMed ID: 29494658
[TBL] [Abstract][Full Text] [Related]
13. Measurement of EBV-IgG anti-VCA avidity aids the early and reliable diagnosis of primary EBV infection.
Robertson P; Beynon S; Whybin R; Brennan C; Vollmer-Conna U; Hickie I; Lloyd A
J Med Virol; 2003 Aug; 70(4):617-23. PubMed ID: 12794726
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of three different assays for the assessment of Epstein Barr Virus immunological status.
Altuglu I; Bozkurt H; Samlioglu P; Zeytinoglu A
New Microbiol; 2007 Oct; 30(4):393-8. PubMed ID: 18080674
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of PCR results in the diagnosis of Epstein-Barr virus infections].
Karadağ Geçgel S; Ersoy A; Sevinir BB; Sınırtaş M; Göral G
Mikrobiyol Bul; 2012 Oct; 46(4):594-606. PubMed ID: 23188573
[TBL] [Abstract][Full Text] [Related]
16. Determination of serological profiles and avidity of specific antibodies in the sera of patients with potential Epstein-Barr virus (EBV) infection.
Akpolat N; Gedik M; Nergiz S; Bilek H
Bratisl Lek Listy; 2013; 114(8):460-3. PubMed ID: 23944621
[TBL] [Abstract][Full Text] [Related]
17. Performance of two commercially available automated immunoassays for the determination of Epstein-Barr virus serological status.
Lupo J; Germi R; Semenova T; Buisson M; Seigneurin JM; Morand P
Clin Vaccine Immunol; 2012 Jun; 19(6):929-34. PubMed ID: 22539474
[TBL] [Abstract][Full Text] [Related]
18. Evidence-based approach for interpretation of Epstein-Barr virus serological patterns.
Klutts JS; Ford BA; Perez NR; Gronowski AM
J Clin Microbiol; 2009 Oct; 47(10):3204-10. PubMed ID: 19656988
[TBL] [Abstract][Full Text] [Related]
19. [Investigation of Epstein-Barr virus and herpes simplex virus markers by serological and molecular methods in patients with rheumatoid arthritis and systemic lupus erythematosus].
Us T; Cetin E; Kaşifoğlu N; Kaşifoğlu T; Akgün Y
Mikrobiyol Bul; 2011 Oct; 45(4):677-83. PubMed ID: 22090298
[TBL] [Abstract][Full Text] [Related]
20. The serological signs of the Epstein-Barr virus (EBV) activity in the elderly.
Ternák G; Szúcs G; Uj M
Acta Microbiol Immunol Hung; 1997; 44(2):133-40. PubMed ID: 9330661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
